Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy

Matteo Vatta, Sonny J. Stetson, Alejandro Perez-Verdia, Mark L. Entman, George P. Noon, Guillermo Torre-Amione, Neil E. Bowles, Jeffrey Towbin

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

Background: Mutations that lead to disruption of cytoskeletal proteins have been recorded in patients with familial dilated cardiomyopathy. We postulated that changes in cytoskeletal and sarcolemmal proteins provide a final common pathway for dilation and contractile dysfunction in dilated cardiomyopathy. In this study, we investigated the integrity of dystrophin in the myocardium of patients with end-stage heart failure due to ischaemic or dilated cardiomyopathy, and the response to treatment with left-ventricular assistance devices (LVAD). Methods: We assessed the expression and integrity of dystrophin in myocardial biopsy samples by immunohistochemistry and western-blot analysis using antibodies against the amino-terminal, carboxyl-terminal, and midrod domains. We took samples from the myocardia of ten controls, ten patients with dilated cardiomyopathy, ten with ischaemic heart disease, and six with dilated cardiomyopathy who underwent placement of a left-ventricular assistance device for progressive refractory heart failure. Findings: Immunohistochemical staining identified a disruption to the amino-terminus of dystrophin in 18 of 20 patients with end-stage cardiomyopathy (dilated or ischaemic), whereas staining with antibodies against other domains of dystrophin was normal. Western-blot analysis confirmed these observations, suggesting that remodelling of dystrophin is a common pathway for dysfunction of failing cardiomyocytes. Furthermore, this disruption was reversible in four patients after LVAD support. Interpretation: Dystrophin remodelling is a useful indicator of left-ventricular function in patients with dilated and ischaemic cardiomyopathy. Our results lend support to the hypothesis that changes in cytoskeletal proteins and, in particular, dystrophin might provide a final common pathway for contractile dysfunction in heart failure and these changes might be reversible by reduction of mechanical stress.

Original languageEnglish (US)
Pages (from-to)936-941
Number of pages6
JournalLancet
Volume359
Issue number9310
DOIs
StatePublished - Mar 16 2002
Externally publishedYes

Fingerprint

Dystrophin
Cardiomyopathies
Dilated Cardiomyopathy
Equipment and Supplies
Cytoskeletal Proteins
Heart Failure
Therapeutics
Myocardium
Western Blotting
Staining and Labeling
Mechanical Stress
Antibodies
Left Ventricular Function
Cardiac Myocytes
Myocardial Ischemia
Dilatation
Immunohistochemistry
Biopsy
Mutation

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. / Vatta, Matteo; Stetson, Sonny J.; Perez-Verdia, Alejandro; Entman, Mark L.; Noon, George P.; Torre-Amione, Guillermo; Bowles, Neil E.; Towbin, Jeffrey.

In: Lancet, Vol. 359, No. 9310, 16.03.2002, p. 936-941.

Research output: Contribution to journalArticle

Vatta, M, Stetson, SJ, Perez-Verdia, A, Entman, ML, Noon, GP, Torre-Amione, G, Bowles, NE & Towbin, J 2002, 'Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy', Lancet, vol. 359, no. 9310, pp. 936-941. https://doi.org/10.1016/S0140-6736(02)08026-1
Vatta, Matteo ; Stetson, Sonny J. ; Perez-Verdia, Alejandro ; Entman, Mark L. ; Noon, George P. ; Torre-Amione, Guillermo ; Bowles, Neil E. ; Towbin, Jeffrey. / Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. In: Lancet. 2002 ; Vol. 359, No. 9310. pp. 936-941.
@article{28bef9563fe144a9a13b161cee971d54,
title = "Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy",
abstract = "Background: Mutations that lead to disruption of cytoskeletal proteins have been recorded in patients with familial dilated cardiomyopathy. We postulated that changes in cytoskeletal and sarcolemmal proteins provide a final common pathway for dilation and contractile dysfunction in dilated cardiomyopathy. In this study, we investigated the integrity of dystrophin in the myocardium of patients with end-stage heart failure due to ischaemic or dilated cardiomyopathy, and the response to treatment with left-ventricular assistance devices (LVAD). Methods: We assessed the expression and integrity of dystrophin in myocardial biopsy samples by immunohistochemistry and western-blot analysis using antibodies against the amino-terminal, carboxyl-terminal, and midrod domains. We took samples from the myocardia of ten controls, ten patients with dilated cardiomyopathy, ten with ischaemic heart disease, and six with dilated cardiomyopathy who underwent placement of a left-ventricular assistance device for progressive refractory heart failure. Findings: Immunohistochemical staining identified a disruption to the amino-terminus of dystrophin in 18 of 20 patients with end-stage cardiomyopathy (dilated or ischaemic), whereas staining with antibodies against other domains of dystrophin was normal. Western-blot analysis confirmed these observations, suggesting that remodelling of dystrophin is a common pathway for dysfunction of failing cardiomyocytes. Furthermore, this disruption was reversible in four patients after LVAD support. Interpretation: Dystrophin remodelling is a useful indicator of left-ventricular function in patients with dilated and ischaemic cardiomyopathy. Our results lend support to the hypothesis that changes in cytoskeletal proteins and, in particular, dystrophin might provide a final common pathway for contractile dysfunction in heart failure and these changes might be reversible by reduction of mechanical stress.",
author = "Matteo Vatta and Stetson, {Sonny J.} and Alejandro Perez-Verdia and Entman, {Mark L.} and Noon, {George P.} and Guillermo Torre-Amione and Bowles, {Neil E.} and Jeffrey Towbin",
year = "2002",
month = "3",
day = "16",
doi = "10.1016/S0140-6736(02)08026-1",
language = "English (US)",
volume = "359",
pages = "936--941",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9310",

}

TY - JOUR

T1 - Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy

AU - Vatta, Matteo

AU - Stetson, Sonny J.

AU - Perez-Verdia, Alejandro

AU - Entman, Mark L.

AU - Noon, George P.

AU - Torre-Amione, Guillermo

AU - Bowles, Neil E.

AU - Towbin, Jeffrey

PY - 2002/3/16

Y1 - 2002/3/16

N2 - Background: Mutations that lead to disruption of cytoskeletal proteins have been recorded in patients with familial dilated cardiomyopathy. We postulated that changes in cytoskeletal and sarcolemmal proteins provide a final common pathway for dilation and contractile dysfunction in dilated cardiomyopathy. In this study, we investigated the integrity of dystrophin in the myocardium of patients with end-stage heart failure due to ischaemic or dilated cardiomyopathy, and the response to treatment with left-ventricular assistance devices (LVAD). Methods: We assessed the expression and integrity of dystrophin in myocardial biopsy samples by immunohistochemistry and western-blot analysis using antibodies against the amino-terminal, carboxyl-terminal, and midrod domains. We took samples from the myocardia of ten controls, ten patients with dilated cardiomyopathy, ten with ischaemic heart disease, and six with dilated cardiomyopathy who underwent placement of a left-ventricular assistance device for progressive refractory heart failure. Findings: Immunohistochemical staining identified a disruption to the amino-terminus of dystrophin in 18 of 20 patients with end-stage cardiomyopathy (dilated or ischaemic), whereas staining with antibodies against other domains of dystrophin was normal. Western-blot analysis confirmed these observations, suggesting that remodelling of dystrophin is a common pathway for dysfunction of failing cardiomyocytes. Furthermore, this disruption was reversible in four patients after LVAD support. Interpretation: Dystrophin remodelling is a useful indicator of left-ventricular function in patients with dilated and ischaemic cardiomyopathy. Our results lend support to the hypothesis that changes in cytoskeletal proteins and, in particular, dystrophin might provide a final common pathway for contractile dysfunction in heart failure and these changes might be reversible by reduction of mechanical stress.

AB - Background: Mutations that lead to disruption of cytoskeletal proteins have been recorded in patients with familial dilated cardiomyopathy. We postulated that changes in cytoskeletal and sarcolemmal proteins provide a final common pathway for dilation and contractile dysfunction in dilated cardiomyopathy. In this study, we investigated the integrity of dystrophin in the myocardium of patients with end-stage heart failure due to ischaemic or dilated cardiomyopathy, and the response to treatment with left-ventricular assistance devices (LVAD). Methods: We assessed the expression and integrity of dystrophin in myocardial biopsy samples by immunohistochemistry and western-blot analysis using antibodies against the amino-terminal, carboxyl-terminal, and midrod domains. We took samples from the myocardia of ten controls, ten patients with dilated cardiomyopathy, ten with ischaemic heart disease, and six with dilated cardiomyopathy who underwent placement of a left-ventricular assistance device for progressive refractory heart failure. Findings: Immunohistochemical staining identified a disruption to the amino-terminus of dystrophin in 18 of 20 patients with end-stage cardiomyopathy (dilated or ischaemic), whereas staining with antibodies against other domains of dystrophin was normal. Western-blot analysis confirmed these observations, suggesting that remodelling of dystrophin is a common pathway for dysfunction of failing cardiomyocytes. Furthermore, this disruption was reversible in four patients after LVAD support. Interpretation: Dystrophin remodelling is a useful indicator of left-ventricular function in patients with dilated and ischaemic cardiomyopathy. Our results lend support to the hypothesis that changes in cytoskeletal proteins and, in particular, dystrophin might provide a final common pathway for contractile dysfunction in heart failure and these changes might be reversible by reduction of mechanical stress.

UR - http://www.scopus.com/inward/record.url?scp=0037117144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037117144&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(02)08026-1

DO - 10.1016/S0140-6736(02)08026-1

M3 - Article

VL - 359

SP - 936

EP - 941

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9310

ER -